Literature DB >> 9350053

Characterization of ligand binding, DNA binding and phosphorylation of progesterone receptor by two novel progesterone receptor antagonist ligands.

C Hurd1, B Underwood, M Herman, K Iwasaki, H J Kloosterboer, S Dinda, V K Moudgil.   

Abstract

In order to gain a better understanding of the distinctive mechanisms of the various types of antiprogestins, we have characterized in vitro ligand binding, specific DNA binding and phosphorylation of progesterone receptor (PR) from T47D cells after treatment of cells with progestins (progesterone, R5020) and antiprogestins (RU486, ZK98299, Org 31806 and Org 31710). Treatment of the cells with R5020 or PR antagonists, with the exception of ZK98299, resulted in a quantitative upshift of PR-A and PR-B indicative of ligand/DNA-induced phosphorylation of PR. Treatment of cells with RU486, Org 31710 or Org 31806, but not R5020 or ZK98299 resulted in detectable PR-progesterone response element complexes (PR-PREc) as assessed by gel mobility shift assay. Although treatment of cells with ZK98299, a type I PR antagonist, did not induce phosphorylation, the antiprogestins, Org 31806 and Org 31710, in a manner identical to RU486, did. Our data suggest that Org 31806 and Org 31710 affect properties of PR from T47D cells that are similar to RU486.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9350053     DOI: 10.1023/a:1006827701940

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  30 in total

Review 1.  The molecular biology of RU486. Is there a role for antiprogestins in the treatment of breast cancer?

Authors:  K B Horwitz
Journal:  Endocr Rev       Date:  1992-05       Impact factor: 19.871

2.  In vivo evidence against the existence of antiprogestins disrupting receptor binding to DNA.

Authors:  K Delabre; A Guiochon-Mantel; E Milgrom
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-15       Impact factor: 11.205

3.  Hormone receptors: their role in predicting prognosis and response to endocrine therapy.

Authors:  W L McGuire
Journal:  Semin Oncol       Date:  1978-12       Impact factor: 4.929

4.  Ligand and DNA-dependent phosphorylation of human progesterone receptor in vitro.

Authors:  M K Bagchi; S Y Tsai; M J Tsai; B W O'Malley
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-01       Impact factor: 11.205

5.  Hormonal chemoprevention of cancer in women.

Authors:  B E Henderson; R K Ross; M C Pike
Journal:  Science       Date:  1993-01-29       Impact factor: 47.728

6.  Dimerization of mammalian progesterone receptors occurs in the absence of DNA and is related to the release of the 90-kDa heat shock protein.

Authors:  A M DeMarzo; C A Beck; S A Onate; D P Edwards
Journal:  Proc Natl Acad Sci U S A       Date:  1991-01-01       Impact factor: 11.205

7.  Two types of anti-progestins have distinct effects on site-specific phosphorylation of human progesterone receptor.

Authors:  C A Beck; Y Zhang; N L Weigel; D P Edwards
Journal:  J Biol Chem       Date:  1996-01-12       Impact factor: 5.157

8.  Steroid hormone-dependent interaction of human progesterone receptor with its target enhancer element.

Authors:  M K Bagchi; J F Elliston; S Y Tsai; D P Edwards; M J Tsai; B W O'Malley
Journal:  Mol Endocrinol       Date:  1988-12

9.  Effects of hormone and cellular modulators of protein phosphorylation on transcriptional activity, DNA binding, and phosphorylation of human progesterone receptors.

Authors:  C A Beck; N L Weigel; D P Edwards
Journal:  Mol Endocrinol       Date:  1992-04

10.  Agonistic and antagonistic activities of RU486 on the functions of the human progesterone receptor.

Authors:  M E Meyer; A Pornon; J W Ji; M T Bocquel; P Chambon; H Gronemeyer
Journal:  EMBO J       Date:  1990-12       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.